Key Highlights

  • Third quarter loss per share was USD 0.58 against an estimated loss of USD 0.50, with no Revenue reported.
  • Net loss was USD 27.3 million, compared with USD 17.1 million in the same quarter last year.
  • Cash and marketable securities were USD 430.2 million at September 30, which the company guided to fund operations into 2029.
  • Updated Factor VII deficiency data are scheduled for the ASH Annual Meeting on December 14.

Hemab Therapeutics (NASDAQ:COAG) held its first quarterly financial results call, reporting a third quarter 2026 loss of USD 0.58 per share against the USD 0.50 estimate. The company reported no revenue. Net loss was USD 27.3 million, up from USD 17.1 million in the same quarter a year earlier.

Cash, cash equivalents and marketable securities were USD 430.2 million as of September 30, compared with USD 457.5 million at June 30. The company continues to guide that its cash funds operations into 2029.

A Pipeline Built Around Bleeding Disorders

Hemab is developing targeted therapies for blood coagulation disorders across three programs. Sutacimig is being developed for Glanzmann thrombasthenia and Factor VII deficiency, which together involve roughly 10,000 patients in the company's key markets. HMB-002 targets Von Willebrand disease, described as the most common inherited bleeding disorder, with about 120,000 diagnosed patients in the same markets. HMB-003 targets heavy menstrual bleeding, which affects more than 23 million women in the United States.

In September the company dosed the first participant in a randomized, placebo-controlled, single-ascending-dose Phase 1 trial of HMB-003 in healthy volunteers. The trial is intended to inform dose selection and development plans in heavy menstrual bleeding and other bleeding conditions with high unmet need. The company noted that no approved non-hormonal, customized hemostatic treatment exists for heavy menstrual bleeding.

Data Calendar Through Early 2027

The company announced first clinical data from its Phase 2b trial of sutacimig in Factor VII deficiency, along with new menstrual bleed data in nonhuman primates treated with HMB-003. Updated Factor VII deficiency data are scheduled for presentation at the ASH Annual Meeting on December 14, and the HMB-003 data on December 13. New data from the HMB-002 program in Von Willebrand disease are scheduled for the EAHAD Congress in February 2027.

Earlier in the year, at the ISTH congress in July, the company made nine presentations and data updates across its three programs, unveiled HMB-003 and dosed the first participant in the Phase 1 trial. Management also introduced a new commercial leader with two decades of experience in launches across rare and common conditions.

What to Track Next

Three dated events frame the coming months: the December ASH presentations, the HMB-002 data in February 2027 and early clinical readouts from the HMB-003 Phase 1 trial. Quarterly cash balance relative to the 2029 runway guidance is the financial marker, since the company reports no revenue.

Management said it plans to use the quarterly forum to share progress, so later calls may add detail on trial timing and spending.